New
Vitiligo drug candidate goes to the finals of The Nature Spinoff Prize
Temprian Therapeutics, a spinoff from Northwestern University with patent for DNA-based vitiligo treatment, has made it to the finals of the Nature Spinoff Prize.
The 12 finalists represent companies from the United States, United Kingdom, Switzerland and Spain operating in pharmaceuticals, predictive assays and medical devices. Temprian’s selection as a finalist for the Nature Spinoff Prize provides hope for securing investment needed for a clinical trial.
The judges will select four companies to participate in a live slam on 13 July. The winner will be awarded the title of 2020 Nature Spin-off Prize champion — and a grant of €30,000 (about US$34,000).
Details of Temprian’s innovation and its underlying patent Mutant HSP70i to Prevent Autoimmune Disease.
FAQOther Questions
- PTSD in Vitiligo?
Living with vitiligo often involves more than managing visible skin changes. Many individuals face discrimination, social stigma, and feelings of isolation, leading to emotional...
- Safety of clinical trials. Can my child leave it for any reason?
Pediatric vitiligo trials · Safety and choice Who watches your child, what may need to pause and what happens if your family changes its mind. Two studies discussed here are eva...
- Can Ayurveda help with vitiligo?
Ayurveda, the ancient Indian system of holistic medicine, focuses on balancing body energies (Doshas) and improving digestion. While it offers a valuable perspective on "whole-b...
Though it is not always easy to treat vitiligo, there is much to be gained by clearly understanding the diagnosis, the future implications, treatment options and their outcomes.
Many people deal with vitiligo while remaining in the public eye, maintaining a positive outlook, and having a successful career.
Copyright (C) Bodolóczki JúliaBy taking a little time to fill in the anonymous questionnaire, you can help researchers better understand and fight vitiligo.